Nanoparticles boost radiation for brain tumors in new trial
NCT ID NCT04899908
First seen Apr 30, 2026 · Last updated May 08, 2026 · Updated 3 times
Summary
This study tests whether adding AGuIX gadolinium-based nanoparticles to standard stereotactic radiation can better control brain metastases that are at higher risk of coming back after radiation alone. About 134 adults with cancers like melanoma, lung, breast, or colorectal cancer that have spread to the brain are participating. The nanoparticles are designed to make radiation more effective at killing tumor cells while sparing healthy tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.